Back to School: How biopharma can reboot drug development. Access exclusive analysis here

R788: Phase II data

In an open-label, dose-escalation, U.S. Phase II trial, 9 of 14 evaluable patients

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE